Skin

Nanophase Reports Record First Quarter Results

Retrieved on: 
Tuesday, April 23, 2024
EDT, PIN, Skin, OTCQB, BASF, Conference, CDT, Beauty, GAAP, Growth

ROMEOVILLE, Ill., April 23, 2024 (GLOBE NEWSWIRE) -- Nanophase Technologies Corporation (OTCQB: NANX), a leader in mineral-based and scientifically-driven health care solutions across beauty and life science categories — with innovations that protect skin from environmental aggressors and aid in medical diagnostics — today announced financial results for the first quarter ended March 31, 2024. 

Key Points: 
  • Jess Jankowski, President and Chief Executive Officer, commented: “We are pleased to have had a successful start to the new year, and a profitable first quarter.
  • Our Company’s largest customer is now on the Solésence side of our business as our brand partners are seeing success in the market.
  • Net income was $0.9 million for the first quarter, vs. a net loss of $1.2 million for the same period in 2023.
  • Nanophase believes that the presentation of results excluding certain items, such as non-cash equity compensation charges, provides meaningful supplemental information to both management and investors, facilitating the evaluation of performance across reporting periods.

ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

Retrieved on: 
Monday, April 22, 2024
Patient, Skin, IGA, Week, Data, Dupilumab, ASLN, Clutch (eggs), Conjunctivitis, ITT, Atopic dermatitis, SAN, Pharmaceutical industry

20% of patients treated with eblasakimab achieved EASI-100 (100% reduction in their EASI score) versus 0% on placebo.

Key Points: 
  • 20% of patients treated with eblasakimab achieved EASI-100 (100% reduction in their EASI score) versus 0% on placebo.
  • The mean reduction in peak pruritus numerical rating scale (PP-NRS) score for eblasakimab-treated patients was 58.9% compared to a 12.9% reduction for placebo.
  • Data from this unique study of dupilumab-experienced AD patients shows eblasakimab has the potential to be highly effective in AD patients even if dupilumab has not been.
  • SAN MATEO, Calif. and SINGAPORE, April 22, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced positive interim results from the Phase 2 study of eblasakimab in moderate-to-severe atopic dermatitis (AD) adult patients previously treated with dupilumab, TREK-DX.

ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months

Retrieved on: 
Monday, April 22, 2024
Skin, GLG, Health, Urbanization, Exosome, Beauty, Growth

Under the agreement, ILIA will have exclusive rights to distribute ELEVAI’s patented skincare products throughout Taiwan.

Key Points: 
  • Under the agreement, ILIA will have exclusive rights to distribute ELEVAI’s patented skincare products throughout Taiwan.
  • ILIA’s near-term sales strategy will be to strategically distribute ELEVAI products to their customers in the country.
  • Chris Kraneiss, Chief Commercial Officer of Elevai Labs, Inc. commented:
    “It is with great pleasure that I announce the signing of ILIA International Ltd. as our exclusive distributor in Taiwan.
  • Asia’s prestige skincare market is projected to grow at 9.9% over the next 5 years6 while the world market averages 3.9%7.

Nanophase Technologies Announces First Quarter 2024 Financial Release and Conference Call Details

Retrieved on: 
Friday, April 19, 2024
CDT, Beauty, Skin, EDT, Conference, PIN, OTCQB, Cryptocurrency

Nanophase will host its First Quarter Conference Call on Wednesday, April 24, 2024, at 10:00 a.m. CDT, 11:00 a.m. EDT, to discuss its financial results and provide a business and financial update.

Key Points: 
  • Nanophase will host its First Quarter Conference Call on Wednesday, April 24, 2024, at 10:00 a.m. CDT, 11:00 a.m. EDT, to discuss its financial results and provide a business and financial update.
  • On the call will be Jess Jankowski, the Company’s President & CEO, joined by Kevin Cureton, the Company’s Chief Operating Officer.
  • Once registered, you will also have the option to have the system dial-out to you once the conference call has begun.
  • The call may also be accessed through the company’s website, at www.nanophase.com , by clicking on Investor Relations, Investor News, and the links in this conference call announcement release.

Kanen Wealth Management Excoriates Fossil Board of Directors and Management for Unacceptably Slow Restructuring Plan

Retrieved on: 
Thursday, April 18, 2024
Debt-to-GDP ratio, Sale, TAG, Skin, Transform, KWM, FOSL, Anxiety, Fossil Group

Judging by the actions of the board and management, there is a lack of urgency in executing its strategic initiatives and returning to profitability.

Key Points: 
  • Judging by the actions of the board and management, there is a lack of urgency in executing its strategic initiatives and returning to profitability.
  • To date, we have little to show as a result of the Transform and Grow plan (TAG).
  • Fossil shares are down approximately 80% since the plan was announced in February 2023.
  • Management needs to take a faster approach in reducing expenses, identify profitable segments, and implement these measures in a rapid cadence.

White Fox Tattoo Studios Introduces Laser Tattoo Removal, Redefining the Art of Ink Transformation in Indiana

Retrieved on: 
Thursday, April 18, 2024
Skin, Safety, Freedom, Mineral oil

NEW HAVEN, Ind., April 18, 2024 (GLOBE NEWSWIRE) -- White Fox Tattoo Studios is an up-and-coming tattoo studio offering services for tattoos and laser tattoo removal featuring the advanced Astanza Duality laser .

Key Points: 
  • NEW HAVEN, Ind., April 18, 2024 (GLOBE NEWSWIRE) -- White Fox Tattoo Studios is an up-and-coming tattoo studio offering services for tattoos and laser tattoo removal featuring the advanced Astanza Duality laser .
  • Their certified laser specialist utilizes powerful laser technology featuring the Astanza Duality, to break down tattoo ink particles and allow the body to naturally absorb and eliminate them.
  • Our studio not only offers exceptional tattoo and cosmetic services, but also provides transformative laser tattoo removal options,” says Lisa Nartker, laser tattoo removal specialist at White Fox Tattoo Studios.
  • Their laser tattoo removal services are available now, and anyone interested is encouraged to schedule a free consultation with their expert laser practitioner.

TransGlobal Assets Inc. provides an update with the Joint-Venture partner Better Health Sciences For Pets Corp.

Retrieved on: 
Thursday, April 18, 2024
VHP, Public, Nature, Outline of health sciences, Pet, Skin, Acupuncture, Health, Massage, OTC, Nose, Hemp, Health Canada, Universal Music Publishing Group, NNS, Happiness, Yoga, Environment, Patient, LP record

CHEYENNE, Wyo., April 18, 2024 (GLOBE NEWSWIRE) -- TransGlobal Assets Inc.'s (OTC: TMSH) joint-venture partner, Better Health Sciences For Pets Corp., has taken a significant step by submitting two additional products to Health Canada for approval as Veterinary Health Products (VHPs).

Key Points: 
  • CHEYENNE, Wyo., April 18, 2024 (GLOBE NEWSWIRE) -- TransGlobal Assets Inc.'s (OTC: TMSH) joint-venture partner, Better Health Sciences For Pets Corp., has taken a significant step by submitting two additional products to Health Canada for approval as Veterinary Health Products (VHPs).
  • This move highlights the commitment of TransGlobal Assets Inc., and Better Health Sciences For Pets Corp., to provide safe, effective, and high-quality products for animal health.
  • By adhering to VHP regulations, they are ensuring the protection of animal health, consumer interests, public health, and the environment.
  • The first product is Better Pets Pet Gel which helps to promote healthy skin and maintain skin health.

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

Retrieved on: 
Thursday, April 18, 2024
Mortality, University, Fibrosis, University of Leeds, TEL, Systemic scleroderma, Synovitis, Nature, Skin, CMMB, Primary sclerosing cholangitis, Prognosis, Communication, Serum, Vascular disease, Physiology, Doctor of Philosophy, Calcinosis, Rheumatology, History, ILD, IND, PSC, Disease, Therapy, Risk, Patient, CSO, Scleroderma, Lung, Clinical trial, CCL24, Pharmaceutical industry

TEL AVIV, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced the publication of a new study that further confirms the key role of its novel soluble protein target CCL24 in systemic sclerosis (SSc). The study, “Serum CCL24 as a Biomarker of Fibrotic and Vascular Disease Severity in Systemic Sclerosis,” was published in the current edition of the journal Arthritis Care and Research.1

Key Points: 
  • It explored the relationship between serum CCL24 levels and SSc severity and prognosis.
  • One in four patients in a real-life SSc population was found to have a high CCL24 serum concentration, despite standard of care treatment with immunosuppressive therapy.
  • The analysis found that higher CCL24 levels were linked to critical clinical variables associated with the most severe forms of SSc.
  • Crucially, high serum CCL24 was predictive of lung deterioration and a higher baseline CCL24 level was associated with higher 10-year SSc-related mortality.

Smith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing’s role in pressure injury prevention  

Retrieved on: 
Thursday, April 18, 2024
Biomedicine, Biomedical engineering, Incidence, FEAE, Skin, Patient, Tel Aviv University, Pressure, PIP, Adhesive

This novel mechanism of action further adds to our understanding of how multi-layer dressings such as ALLEVYN LIFE work when used prophylactically for PIP.1

Key Points: 
  • This novel mechanism of action further adds to our understanding of how multi-layer dressings such as ALLEVYN LIFE work when used prophylactically for PIP.1
    “Based on my extensive, decades-long research in pressure ulcer/injury prevention, I am certain that an effective prevention dressing must contain a shear mitigation mechanism,” said Amit Gefen, Professor of Biomedical Engineering at Tel Aviv University.
  • “My recent study published in the International Wound Journal on ALLEVYN LIFE Dressing revealed the role of its unique internal frictional layer-on-layer sliding which, together with its specific construct and material composition, facilitate effective shear mitigation.”
    “Pressure injuries have a high burden on patients and healthcare systems,” said Rohit Kashyap, President, Advanced Wound Management at Smith+Nephew.
  • A new metric, frictional energy absorber effectiveness (FEAE), was also introduced to quantify the total mechanical energy dissipation of ALLEVYN LIFE Dressing.1
    This newly discovered mechanism of action for ALLEVYN LIFE Dressing further adds, and gives context to, the already existing wealth of clinical evidence9 for its capabilities in PIP that demonstrate significant reduction in pressure injury incidence.
  • *1

Bestqool proves the effectiveness and safety of its red light therapy device with a professional third-party Report

Retrieved on: 
Wednesday, April 17, 2024
Physical, Enzyme, Cell, RLT, Safety, Skin, Tissue, Bacteria, NASA, Weight loss, System, Carbon, Plant, Mitochondrion, Oxygen, Phagocytosis, Vasodilation, Medicine, Virus, Nutrient, Regeneration, Food preservation

Bestqool , a leading manufacturer in the industry of red light therapy, offers lifestyle game-changing devices that prioritize safety, efficacy, and user comfort.

Key Points: 
  • Bestqool , a leading manufacturer in the industry of red light therapy, offers lifestyle game-changing devices that prioritize safety, efficacy, and user comfort.
  • The utilization of red light therapy in well-being has its roots dating back to ancient Greek times.
  • Unlike ultraviolet light, red light is harmless to the skin and does not tan or cause dark spots to the skin.
  • One of the crucial factors that the reader needs to pay attention to when buying red light therapy is RLT device irradiance.